Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for September 29, 2022

9/29/2022

 
The FDA approved elivaldogene autotemcel (Skysona, bluebird bio), on 9/16/2022, to slow the progression of neurologic dysfunction in early, active cerebral adrenoleukodystrophy (CALD). Elivaldogene autotemcel will only be available at Qualified Treatment Centers (QTC), selected by Bluebird. The cost for the one-time treatment is $3 million. Unlike betibeglogene autotemcel, bluebird bio will not offer an outcomes-based payment plan with rebates for patients that do not respond for elivaldogene autotemcel.
 
In September 2022, the FDA allowed Merck to proceed with two HIV-1 trials evaluating a lower dose of islatravir in combination with doravirine and a second trial in combination with lenacapavir.
 
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 13-4 to recommend RBX2660 to reduce recurrent C. difficile infection after antibiotic treatment.
 
Vertex and CRISPR Therapeutic initiated a rolling BLA submission for exagamglogene autotemcel for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
 
The FDA has placed a hold on the Phase III VITESSE trial, evaluating Viaskin Peanut, until DBV makes changes to the study protocol regarding statistical analysis and total number of patients.
 
The FDA has designated dovitinib a Rare Pediatric Disease treatment for osteosarcoma.
 
Botanix Pharmaceuticals submitted an NDA for sofpironium bromide gel for the treatment of severe primary axillary hyperhidrosis.
 
The European Commission (EC) approved:
  • Faricimab (Vabysmo, Roche) for the treatment of neovascular macular degeneration and visual impairment due to diabetic macular edema.
  • Tezepelumab (Tezspire) as add-on maintenance treatment of severe asthma in patients who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.
  • Fosdenopterin (Nulibry, BridgeBio Pharma and Sentynl Therapeutics) to reduce the risk of death due to Molybdenum Cofactor Deficiency Type A.​
CHMP recommended approval of:
  • Nirsevimab (Beyfortus, AstraZeneca & Sanofi) for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants.
  • Sutimlimab (Enjaymo, Sanofi) for the treatment of hemolytic anaemia.
  • Maribavir (Livtencity, Takeda, ViroPharma, Shire) for the treatment of cytomegalovirus infection.
  • Mitapivat (Pyrukynd, Agios Pharmaceuticals) to treat pyruvate kinase deficiency.
  • Loncastuximab tesirine (Zynlonta, ADC Therapeutics) for a conditional marketing authorization to treat diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.